浙江医药：XC2309注射液获药物临床试验批准通知书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the clinical trial of XC2309 injection, which is intended for treating gastrointestinal ulcer bleeding [1] Summary by Categories Regulatory Approval - The National Medical Products Administration has issued a clinical trial approval notice for XC2309 injection, confirming that the application meets the requirements for drug registration [1] Product Development - XC2309 injection is designed to address gastrointestinal ulcer bleeding caused by various conditions [1] - The company has invested a total of 83.9607 million yuan in the research and development of the XC2309 project to date [1]